PROLENE POLYPROPYLENE MESH UNKNOWN PRODUCT
Report
- Report Number
- 2210968-2019-85609
- Event Type
- Injury
- Date Received
- August 15, 2019
- Report Date
- July 18, 2019
- Manufacturer
- ETHICON INC.
- Product Code
- FTL
- PMA / PMN Number
- K962530
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- GM
- Reporter Occupation
- OTHER
Narratives
(B)(4). THIS REPORT IS RELATED TO A JOURNAL ARTICLE; THEREFORE, NO PRODUCT WILL BE RETURNED FOR ANALYSIS AND THE BATCH HISTORY RECORDS CANNOT BE REVIEWED AS THE LOT NUMBER HAS NOT BEEN PROVIDED. THE SINGLE COMPLAINT WAS REPORTED WITH MULTIPLE EVENTS. THERE ARE NO ADDITIONAL DETAILS REGARDING THE ADDITIONAL EVENTS. CITATION: SURG ENDOSC (2008) 22:1790¿1797; DOI 10.1007/S00464-008-9863-6. (B)(4).
TITLE: SIXTY-MONTH FOLLOW-UP AFTER ENDOSCOPIC INGUINAL HERNIA REPAIR WITH THREE TYPES OF MESH: A PROSPECTIVE RANDOMIZED TRIAL. THIS PROSPECTIVE, CLINICAL, RANDOMIZED, DOUBLE-BLIND STUDY AIMED TO INVESTIGATE THE IMPACT OF THE STRUCTURE AND THE AMOUNT OF POLYPROPYLENE (PP) MESH USED IN LAPAROSCOPIC TRANSABDOMINAL PREPERITONEAL HERNIOPLASTIC (TAPP) ON PHYSICAL FUNCTION AND LIFE QUALITY. BETWEEN 1999 AND 2001, 180 MALE PATIENTS WITH PRIMARY INGUINAL HERNIA UNDERGOING TAPP WERE RANDOMIZED FOR USING A HEAVYWEIGHT (108 G/M2), DOUBLE-FILAMENT PP MESH (PROLENE, 10 X 15 CM, GROUP A) (N=60, MEAN AGE 61.5±3.4 YEARS); A MULTIFILAMENT, HEAVYWEIGHT VARIANT (116 G/M2) OF PP MESH (SERAPREN, 10 X 15 CM, GROUP B) (N=60, MEAN AGE 62.3±4.3 YEARS), OR A COMPOSITE MESH (POLYGLACTIN AND PP) (VYPRO II, 10 X 15 CM, GROUP C) (N=60, MEAN AGE 63.3±3.8 YEARS). WE DID NOT CUT ANY SLITS IN THE MESHES. WE TRIED TO USE THE MINIMUM NUMBER OF CLIPS ON COOPER¿S LIGAMENT, MEDIAL AND LATERAL TO THE EPIGASTRIC VESSELS WITH STRAIGHT ENDOSTAPLER, (ETHICON, (B)(6)). THE PERITONEUM WAS ALSO CLOSED WITH A RESORBABLE SUTURE (ETHICON, VYCRYL 3/0). COMPLICATIONS IN GROUP A (PROLENE GROUP) INCLUDED SCROTAL HEMATOMA (N=3), ABDOMINAL WALL SEROMA (N=8) AND TESTICULAR CONTACT PAIN (N=3) IN POST-OPERATIVE DAY 1; SCROTAL HEMATOMA (N=12), ABDOMINAL WALL SEROMA (N=10) AND TESTICULAR CONTACT PAIN (N=8) IN POST-OPERATIVE DAY 2; SCROTAL HEMATOMA (N=12), ABDOMINAL WALL SEROMA (N=8) AND TESTICULAR CONTACT PAIN (N=4), PAIN WITH EJACULATION (N=5), DISCOMFORT WITH URINATION (N=8) IN POST-OPERATIVE WEEK 1; SCROTAL HEMATOMA (N=12), ABDOMINAL WALL SEROMA (N=8) AND TESTICULAR CONTACT PAIN (N=7), PAIN WITH EJACULATION (N=10), DISCOMFORT WITH URINATION (N=7) IN POST-OPERATIVE WEEK 2; SCROTAL HEMATOMA (N=8), ABDOMINAL WALL SEROMA (N=6) AND TESTICULAR CONTACT PAIN (N=7), PAIN WITH EJACULATION (N=12), DISCOMFORT WITH URINATION (N=7) IN POST-OPERATIVE WEEK 4; TESTICULAR CONTACT PAIN (N=8), PAIN WITH EJACULATION (N=12), DISCOMFORT WITH URINATION (N=7) IN POST-OPERATIVE WEEK 12; PAIN WITH EJACULATION (N=2), DISCOMFORT WITH URINATION (N=2) AND RECURRENCE RATE (N=1) IN POST-OPERATIVE MONTH 24 AND PAIN WITH EJACULATION (N=1), DISCOMFORT WITH URINATION (N=1) AND RECURRENCE RATE (N=1) IN POST-OPERATIVE MONTH 60. COMPLICATIONS IN GROUP B (SERAPREN GROUP) INCLUDED SCROTAL HEMATOMA (N=2), ABDOMINAL WALL SEROMA (N=6) AND TESTICULAR CONTACT PAIN (N=4) IN POST-OPERATIVE DAY 1; SCROTAL HEMATOMA (N=10), ABDOMINAL WALL SEROMA (N=8) AND TESTICULAR CONTACT PAIN (N=6) IN POST-OPERATIVE DAY 2; SCROTAL HEMATOMA (N=10), ABDOMINAL WALL SEROMA (N=7) AND TESTICULAR CONTACT PAIN (N=4), PAIN WITH EJACULATION (N=6), DISCOMFORT WITH URINATION (N=5) IN POST-OPERATIVE WEEK 1; SCROTAL HEMATOMA (N=10), ABDOMINAL WALL SEROMA (N=6) AND TESTICULAR CONTACT PAIN (N=3), PAIN WITH EJACULATION (N=6), DISCOMFORT WITH URINATION (N=3) IN POST-OPERATIVE WEEK 2; SCROTAL HEMATOMA (N=6), ABDOMINAL WALL SEROMA (N=4) AND TESTICULAR CONTACT PAIN (N=2), PAIN WITH EJACULATION (N=4), DISCOMFORT WITH URINATION (N=2) IN POST-OPERATIVE WEEK 4; TESTICULAR CONTACT PAIN (N=1), PAIN WITH EJACULATION (N=2), DISCOMFORT WITH URINATION (N=1) IN POST-OPERATIVE WEEK 12; DISCOMFORT WITH URINATION (N=1) IN POST-OPERATIVE MONTH 24. COMPLICATIONS IN GROUP C (VYPRO II GROUP) INCLUDED SCROTAL HEMATOMA (N=2), ABDOMINAL WALL SEROMA (N=6) AND TESTICULAR CONTACT PAIN (N=4) IN POST-OPERATIVE DAY 1; SCROTAL HEMATOMA (N=10), ABDOMINAL WALL SEROMA (N=8) AND TESTICULAR CONTACT PAIN (N=7) IN POST-OPERATIVE DAY 2; SCROTAL HEMATOMA (N=10), ABDOMINAL WALL SEROMA (N=8) AND TESTICULAR CONTACT PAIN (N=4), PAIN WITH EJACULATION (N=4), DISCOMFORT WITH URINATION (N=4) IN POST-OPERATIVE WEEK 1; SCROTAL HEMATOMA (N=10), ABDOMINAL WALL SEROMA (N=7) AND TESTICULAR CONTACT PAIN (N=2), PAIN WITH EJACULATION (N=4), DISCOMFORT WITH URINATION (N=4) IN POST-OPERATIVE WEEK 2; SCROTAL HEMATOMA (N=6), ABDOMINAL WALL SEROMA (N=2) AND TESTICULAR CONTACT PAIN (N=2), PAIN WITH EJACULATION (N=4), DISCOMFORT WITH URINATION (N=3) IN POST-OPERATIVE WEEK 4; TESTICULAR CONTACT PAIN (N=2), PAIN WITH EJACULATION (N=2), DISCOMFORT WITH URINATION (N=2) IN POST-OPERATIVE WEEK 12; PAIN WITH EJACULATION (N=1), DISCOMFORT WITH URINATION (N=1) AND RECURRENCE RATE (N=1) IN POST-OPERATIVE MONTH 24 AND RECURRENCE RATE (N=1) IN POST-OPERATIVE MONTH 60. IN CONCLUSION, THE COMPOSITE MESH DOES NOT PROVIDE AN ADVANTAGE CONCERNING PHYSICAL FUNCTION OR PAIN DEVELOPMENT IN COMPARISON TO THE MULTIFILAMENT, HEAVYWEIGHT, PURE POLYPROPYLENE MESH. INDEPENDENTLY OF WHICH MESH WAS IMPLANTED 5% OF PATIENTS ARE STILL SUFFERING FROM DISCOMFORT AFTER 5 YEARS.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 692338 | PROLENE POLYPROPYLENE MESH UNKNOWN PRODUCT | MESH, SURGICAL, POLYMERIC | FTL | ETHICON INC. |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | Required Intervention |